Indeterminate Colitis – Update on Treatment Options

References

• Maher MM. Inflammatory bowel disease: review and future view. Front Biosci. 2012;4:1638–1647. doi:10.2741/e485
   Google Scholar
• Meucci G, Bortoli A, Riccioli FA, et al. Frequency and clinical evolution of indeterminate colitis: a retrospective multi-centre study in northern Italy. GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali). Eur J Gastroenterol Hepatol. 1999;11(8):909–913. doi:10.1097/00042737-199908000-00018
   PubMed Web of Science ®Google Scholar
• Geboes K, Colombel JF, Greenstein A, et al. Indeterminate colitis: a review of the concept–what’s in a name? Inflamm Bowel Dis. 2008;14(6):850–857. doi:10.1002/ibd.20361
   PubMed Web of Science ®Google Scholar
• Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease–“colitis indeterminate”. J Clin Pathol. 1978;31(6):567–577. doi:10.1136/jcp.31.6.567
   PubMed Web of Science ®Google Scholar
• Kent TH, Ammon RK, DenBesten L. Differentiation of ulcerative colitis and regional enteritis of colon. Arch Pathol. 1970;89(1):20–29.
   PubMedGoogle Scholar
• Emad Mansoor FJ-D, Cheema T, Saleh MA, Regueiro M, Katz J, Cooper GS. Epidemiology of indeterminate colitis in the United States between 2014 and 2019: a Population-Based National Study. Am J Gastroenterol. 2019;114(p):S1594. doi:10.14309/01.ajg.0000601220.52856.c5
   Google Scholar
• Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48(2):116–132. doi:10.1111/j.1365-2559.2005.02248.x
   PubMed Web of Science ®Google Scholar
• Tremaine WJ. Is indeterminate colitis determinable? Curr Gastroenterol Rep. 2012;14(2):162–165. doi:10.1007/s11894-012-0244-x
   PubMedGoogle Scholar
• Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233–1244. doi:10.1136/jcp.2003.015214
   PubMed Web of Science ®Google Scholar
• Farmer M, Petras RE, Hunt LE, Janosky JE, Galandiuk S. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3184–3188. doi:10.1111/j.1572-0241.2000.03199.x
   PubMed Web of Science ®Google Scholar
• Odze RD. A contemporary and critical appraisal of “indeterminate colitis”. Mod Pathol. 2015;28(Suppl 1):S30–46. doi:10.1038/modpathol.2014.131
   PubMedGoogle Scholar
• Geboes K, De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis. 2003;9(5):324–331. doi:10.1097/00054725-200309000-00007
   PubMed Web of Science ®Google Scholar
• Rudolph WG, Uthoff SM, McAuliffe TL, Goode ET, Petras RE, Galandiuk S. Indeterminate colitis: the real story. Dis Colon Rectum. 2002;45(11):1528–1534. doi:10.1007/s10350-004-6461-0
   PubMed Web of Science ®Google Scholar
• Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008;14(3):354–377. doi:10.3748/wjg.14.354
   PubMed Web of Science ®Google Scholar
• Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45(6):571–583. doi:10.1007/s00535-010-0219-3
   PubMed Web of Science ®Google Scholar
• Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3(5):893–903.
   PubMedGoogle Scholar
• Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110(1):114–126. doi:10.1038/ajg.2014.357
   PubMed Web of Science ®Google Scholar
• Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA technical review on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):769–808 e729. doi:10.1053/j.gastro.2018.12.008
   PubMed Web of Science ®Google Scholar
• Tian C, Huang Y, Wu X, Xu C, Bu H, Wang H. The efficacy and safety of mesalamine and probiotics in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2020;2020:6923609. doi:10.1155/2020/6923609
   PubMed Web of Science ®Google Scholar
• Burakoff R. Indeterminate colitis: clinical spectrum of disease. J Clin Gastroenterol. 2004;38(5 Suppl 1):S41–43. doi:10.1097/01.mcg.0000123991.13937.7e
   PubMed Web of Science ®Google Scholar
• Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63(3):629–642. doi:10.1016/S1734-1140(11)70575-8
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):590–599; quiz 600. doi:10.1038/ajg.2011.70
   Web of Science ®Google Scholar
• Salameh R, Kirchgesner J, Allez M, et al. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther. 2020;51(11):1096–1104. doi:10.1111/apt.15751
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–765e752; quiz e714–755. doi:10.1053/j.gastro.2013.04.048
   PubMed Web of Science ®Google Scholar
• McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2012;12:CD003459. doi:10.1002/14651858.CD003459.pub3
   PubMed Web of Science ®Google Scholar
• Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16(4):693–697. doi:10.1046/j.1365-2036.2002.01227.x
   PubMed Web of Science ®Google Scholar
• Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005;21(4):385–389. doi:10.1111/j.1365-2036.2005.02331.x
   PubMed Web of Science ®Google Scholar
• Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12(11):1227–1233. doi:10.1097/00042737-200012110-00010
   PubMed Web of Science ®Google Scholar
• Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110(5):1416–1421. doi:10.1053/gast.1996.v110.pm8613046
   PubMed Web of Science ®Google Scholar
• Heron V, Loftus EV Jr. Nonbiologic immune suppression in ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):731–738. doi:10.1016/j.gtc.2020.07.003
   PubMed Web of Science ®Google Scholar
• Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist’s treatment in pediatric Crohn’s disease. J Crohns Colitis. 2013;7(5):369–376. doi:10.1016/j.crohns.2012.03.006
   PubMed Web of Science ®Google Scholar
• Hannoodee M, Mittal M. Methotrexate. In: StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol. 2009;36(6):610–614. doi:10.1080/003655201750163051
   Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841–1845. doi:10.1056/NEJM199406303302601
   PubMed Web of Science ®Google Scholar
• Ogata H, Matsui T, Nakamura M, Hirai F, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in the management of hospitalized patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803–808. doi:10.1002/ibd.21853
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–1811. doi:10.1053/j.gastro.2005.03.003
   PubMed Web of Science ®Google Scholar
• Sedano R, Almradi A, Ma C, Jairath V, Feagan BG. Novel therapeutics for the treatment of ibd: current status and future directions. Curr Treat Options Gastroenterol. 2020;18:442–461. doi:10.1007/s11938-020-00299-7
   Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. doi:10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721. doi:10.1056/NEJMoa1215739
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562–572 e512. doi:10.1053/j.gastro.2019.08.027
   PubMed Web of Science ®Google Scholar
• Sands BE, Schreiber S, Lirio RA. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. reply. N Engl J Med. 2020;382(1):93–94. doi:10.1056/NEJMc1915739
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi:10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi:10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Ochsenkuhn T, Tillack C, Szokodi D, et al. Clinical Outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United Eur Gastroenterol J. 2019;8(1):91–98. doi:10.1177/2050640619895361
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003;18(7):741–747. doi:10.1046/j.1365-2036.2003.01739.x
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther. 2010;31(9):1036–1041. doi:10.1111/j.1365-2036.2010.04267.x
   PubMed Web of Science ®Google Scholar
• Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum. 2000;43(11):1487–1496. doi:10.1007/BF02236726
   PubMed Web of Science ®Google Scholar
• McIntyre PB, Pemberton JH, Wolff BG, Dozois RR, Beart RW Jr. Indeterminate colitis. Long-term outcome in patients after ileal pouch-anal anastomosis. Dis Colon Rectum. 1995;38(1):51–54. doi:10.1007/BF02053857
   PubMed Web of Science ®Google Scholar
• Atkinson KG, Owen DA, Wankling G. Restorative proctocolectomy and indeterminate colitis. Am J Surg. 1994;167(5):516–518. doi:10.1016/0002-9610(94)90248-8
   PubMed Web of Science ®Google Scholar
• Koltun WA, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. Dis Colon Rectum. 1991;34(10):857–860. doi:10.1007/BF02049696
   PubMed Web of Science ®Google Scholar
• Murrell ZA, Melmed GY, Ippoliti A, et al. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. Dis Colon Rectum. 2009;52(5):872–878. doi:10.1007/DCR.0b013e31819f5d4c
   PubMed Web of Science ®Google Scholar
• Brown CJ, MacLean AR, Cohen Z, Macrae HM, O’Connir B, McLeod RS. Crohn’s disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis Colon Rectum. 2005;48(8):1542–1549. doi:10.1007/s10350-005-0059-z
   PubMed Web of Science ®Google Scholar
• Pishori T, Dinnewitzer A, Zmora O, et al. Outcome of patients with indeterminate colitis undergoing a double-stapled ileal pouch-anal anastomosis. Dis Colon Rectum. 2004;47(5):717–721. doi:10.1007/s10350-003-0116-4
   PubMed Web of Science ®Google Scholar
• Dayton MT, Larsen KR, Christiansen DD. Similar functional results and complications after ileal pouch-anal anastomosis in patients with indeterminate vs ulcerative colitis. Arch Surg. 2002;137(6):690–694; discussion 694–695. doi:10.1001/archsurg.137.6.690
   PubMedGoogle Scholar
• Jackson KL, Stocchi L, Duraes L, Rencuzogullari A, Bennett AE, Remzi FH. Long-term outcomes in indeterminate colitis patients undergoing ileal pouch-anal anastomosis: function, quality of life, and complications. J Gastrointest Surg. 2017;21(1):56–61. doi:10.1007/s11605-016-3306-9
   PubMed Web of Science ®Google Scholar
• Netz U, Galbraith NJ, O’Brien S, et al. Long-term outcomes following ileal pouch-anal anastomosis in patients with indeterminate colitis. Surgery. 2018;163(3):535–541. doi:10.1016/j.surg.2017.11.014
   PubMed Web of Science ®Google Scholar
• Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 1996;39(8):893–898. doi:10.1007/BF02053988
   PubMed Web of Science ®Google Scholar
• Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017;23(5):781–790. doi:10.1097/MIB.0000000000001061
   PubMed Web of Science ®Google Scholar
• Emile SH, Gilshtein H, Wexner SD. Outcome of ileal pouch-anal anastomosis in patients with indeterminate colitis: a systematic review and meta-analysis. J Crohns Colitis. 2020;14(7):1010–1020. doi:10.1093/ecco-jcc/jjaa002
   PubMed Web of Science ®Google Scholar
• Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242–1247. doi:10.1053/gast.2002.32980
   PubMed Web of Science ®Google Scholar
• Sura SP, Ahmed A, Cheifetz AS, Moss AC. Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol. 2014;48(4):351–355. doi:10.1097/MCG.0000000000000083
   PubMed Web of Science ®Google Scholar
• Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005;3(1):60–66. doi:10.1016/S1542-3565(04)00604-4
   PubMed Web of Science ®Google Scholar
• Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2019;11:CD001176. doi:10.1002/14651858.CD001176.pub5
   PubMedGoogle Scholar
• Ribaldone DG, Pellicano R, Saracco GM, Morino M, Astegiano M. Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis. Rev Esp Enferm Dig. 2020;112(1):59–63. doi:10.17235/reed.2019.6336/2019
   PubMed Web of Science ®Google Scholar
• Ollech JE, Rubin DT, Glick L, et al. Ustekinumab is effective for the treatment of chronic antibiotic-refractory pouchitis. Dig Dis Sci. 2019;64(12):3596–3601. doi:10.1007/s10620-019-05697-1
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108–114. doi:10.1136/gut.53.1.108
   PubMed Web of Science ®Google Scholar
• Lucha PA Jr, Fticsar JE, Francis MJ. The strictured anastomosis: successful treatment by corticosteroid injections–report of three cases and review of the literature. Dis Colon Rectum. 2005;48(4):862–865. doi:10.1007/s10350-004-0838-y
   PubMed Web of Science ®Google Scholar
• Cao Y, Su Q, Zhang B, Shen F, Li S. Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther. 2021;12(1):32. doi:10.1186/s13287-020-02095-7
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of ibd diagnosis in the Swiss inflammatory bowel disease cohort. Inflamm Bowel Dis. 2015;21(8):1794–1800. doi:10.1097/MIB.0000000000000429
   PubMed Web of Science ®Google Scholar
• Kirsch R, Pentecost M, Hall Pde M, Epstein DP, Watermeyer G, Friederich PW. Role of colonoscopic biopsy in distinguishing between Crohn’s disease and intestinal tuberculosis. J Clin Pathol. 2006;59(8):840–844. doi:10.1136/jcp.2005.032383
   PubMed Web of Science ®Google Scholar
• Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–595. doi:10.1038/nrgastro.2013.117
   PubMed Web of Science ®Google Scholar
• Guillo L, D’Amico F, Serrero M, et al. Assessment of extraintestinal manifestations in inflammatory bowel diseases: a systematic review and a proposed guide for clinical trials. United Eur Gastroenterol J. 2020;8(9):1013–1030. doi:10.1177/2050640620950093
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Van Assche G, Gomez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15(1):25–36 e27. doi:10.1016/j.cgh.2016.06.025
   PubMed Web of Science ®Google Scholar
• Goodhand JR, Alazawi W, Rampton DS. Systematic review: clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33(4):428–441. doi:10.1111/j.1365-2036.2010.04548.x
   PubMed Web of Science ®Google Scholar
• Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775–778. doi:10.1097/01.meg.0000131040.38607.09
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(4):976–983. doi:10.1002/ibd.21457
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6(3):330–336. doi:10.1016/j.crohns.2011.09.005
   PubMed Web of Science ®Google Scholar
• McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13(1):131–137; quiz e137. doi:10.1016/j.cgh.2014.05.026
   Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268–1276. doi:10.1038/ajg.2013.138
   PubMed Web of Science ®Google Scholar
• Agrawal M, Arora S, Li J, et al. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep. 2011;9(4):251–257. doi:10.1007/s11914-011-0077-9
   PubMedGoogle Scholar
• Targownik LE, Bernstein CN, Leslie WD. Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol. 2014;30(2):168–174. doi:10.1097/MOG.0000000000000037
   PubMed Web of Science ®Google Scholar
• Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. Osteoporos Int. 2017;28(12):3301–3314. doi:10.1007/s00198-017-4189-7
   PubMed Web of Science ®Google Scholar
• Paschou SA, Kothonas F, Lafkas A, et al. Favorable effect of anti-TNF therapy on insulin sensitivity in nonobese, nondiabetic patients with inflammatory bowel disease. Int J Endocrinol. 2018;2018:6712901. doi:10.1155/2018/6712901
   PubMed Web of Science ®Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. doi:10.1136/annrheumdis-2017-211555
   PubMed Web of Science ®Google Scholar
• Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe crohn’s disease: a Phase 2a Study. Gastroenterology. 2017;153(1):77–86 e76. doi:10.1053/j.gastro.2017.03.049
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736. doi:10.1056/NEJMoa1606910
   PubMed Web of Science ®Google Scholar
• Panes J, Vermeire S, Lindsay JO, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis. 2018;12(2):145–156. doi:10.1093/ecco-jcc/jjx133
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–275. doi:10.1016/S0140-6736(16)32537-5
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384. doi:10.1016/S0140-6736(21)00666-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–1762. doi:10.1056/NEJMoa1513248
   PubMed Web of Science ®Google Scholar
• Prenzel F, Uhlig HH. Frequency of indeterminate colitis in children and adults with IBD - a metaanalysis. J Crohns Colitis. 2009;3(4):277–281. doi:10.1016/j.crohns.2009.07.001
   PubMed Web of Science ®Google Scholar
• Aloi M, Birimberg-Schwartz L, Buderus S, et al. Treatment options and outcomes of pediatric ibdu compared with other IBD subtypes: a retrospective multicenter study from the IBD porto group of ESPGHAN. Inflamm Bowel Dis. 2016;22(6):1378–1383. doi:10.1097/MIB.0000000000000767
   PubMed Web of Science ®Google Scholar